Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008

NEXT STORY
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
PREV STORY
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cellect Biotechnology Reports First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Adjusted Operations Due to COVID-19

author_avatar
NASDAQ Market News

Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone

author_avatar
NASDAQ Market News

NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting

AMES, Iowa, June 20, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced ...

author_avatar
NASDAQ Market News